- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Acoustic Imaging keeps its identity
Ultrasound vendor Acoustic Imaging of Phoenix has abandoned plansannounced late last year to retire its name and corporate logoin favor of that of parent Dornier Medizintechnik (SCAN 11/22/95).The Acoustic Imaging marque will live on as part of
Ultrasound vendor Acoustic Imaging of Phoenix has abandoned plansannounced late last year to retire its name and corporate logoin favor of that of parent Dornier Medizintechnik (SCAN 11/22/95).The Acoustic Imaging marque will live on as part of Dornier'snew logo, which was released late last month.
Acoustic Imaging decided to keep its name after members ofthe ultrasound community said they opposed the change, accordingto Steven Kaska, worldwide director of marketing and marketingcommunications.
"We went out to some of our key physicians, and they allfelt it was a mistake to drop a 10-year identity," Kaskasaid. "We can't argue with that."
Dornier's new logo, a human-like figure with outstretched arms,replaces the four-point star used by former Dornier parent Daimler-BenzAerospace (DASA). DASA sold a majority interest in Dornier toSingapore Technologies in February (SCAN 2/28/96). Acoustic Imaging,Dornier Medical Systems, and other DMT companies will use thenew logo along with their own company names.
In other Acoustic Imaging news, the company has finalized anagreement with Fischer Imaging of Denver in which Fischer willmarket AI's Performa ultrasound scanner in conjunction with Fischer'sMammotest breast biopsy system (SCAN 6/5/96). AI will continueto sell Performa in stand-alone situations.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
